SCHEMBL20071774

SCHEMBL20071774

CC(C)(C)c1ccc2c(c1)N(c1ccc(-c3ccccc3)s1)C(C1N(c3ccc(-c4ccccc4)s3)c3ccc(C(C)(C)C)cc3N1c1ccc(-c3ccccc3)s1)N2c1ccc(-c2ccccc2)s1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.38
HSD17B1 P14061 3/20 0.36
HSD17B2 P37059 3/20 0.36
PRKDC P78527 2/20 0.36
CYP2E1 P05181 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2A6 P11509 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2B6 P20813 1/20 0.33
CYP2C19 P33261 1/20 0.33
NQO2 P16083 1/20 0.33
P2RX3 P56373 1/20 0.33
CYP11B1 P15538 1/20 0.32
CYP11B2 P19099 1/20 0.32
RXRA P19793 1/20 0.32
RXRB P28702 1/20 0.32
KIF11 P52732 1/20 0.32
NR1H3 Q13133 1/20 0.31
OPRL1 P41146 1/20 0.30
KDM4E B2RXH2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20062960 0.84 AR (0.38) ARHSD17B1HSD17B2PRKDCCYP2E1
SCHEMBL20071773 0.79 MAPT (0.34) ALDH1A1HPGDMAPK1
SCHEMBL20071952 0.77 RXRB (0.32) PRKDCRXRARXRB
SCHEMBL20097508 0.72 HSD17B1 (0.55) HSD17B1HSD17B2CYP2E1CYP3A4CYP2A6
SCHEMBL20681879 0.72 MEN1 (0.39) KIF11NR1H3KDM4EHPGDRAB9A
SCHEMBL17994290 0.70 HSD17B1 (0.52) HSD17B1HSD17B2CYP2E1CYP3A4CYP2A6
SCHEMBL20071967 0.70 HPGD (0.34) PRKDCCYP2E1CYP3A4CYP2A6CYP2C9
SCHEMBL19735289 0.69 KIF11 (0.55) HSD17B1HSD17B2CYP2E1CYP3A4CYP2A6
SCHEMBL20071890 0.68 CHRNB2 (0.43) CYP3A4CYP11B1CYP11B2RXRA
SCHEMBL25777967 0.67 L3MBTL1 (0.38) KIF11NR1H3NPC1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10541260-B2 Organic photoelectric conversion element, optical area sensor, imaging device, and imaging apparatus CANON KABUSHIKI KAISHA (JP) 2020-01-21 US disclosed
US-10193084-B2 2,2′-bibenzo[D]imidazolidene compound having heteromonocyclic groups at the 1-, 1′-, 3- and 3′- positions, and organic light-emitting element and display device containing the same CANON KABUSHIKI KAISHA (JP) 2019-01-29 US disclosed
US-20180108691-A1 ORGANIC PHOTOELECTRIC CONVERSION ELEMENT, OPTICAL AREA SENSOR, IMAGING DEVICE, AND IMAGING APPARATUS CANON KABUSHIKI KAISHA (JP) 2018-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10193084-B2 2,2′-bibenzo[D]imidazolidene compound having heteromonocyclic groups at the 1-, 1′-, 3- and 3′- positions, and organic light-emitting element and display device containing the same BRD1, DRD1, NR2E3 AR 75/4885HSD17B1 1751/4885HSD17B2 1310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.